A heterogeneous group of sporadic or familial disorders characterized by AMYLOID deposits in the walls of small and medium sized blood vessels of CEREBRAL CORTEX and MENINGES. Clinical features include multiple, small lobar CEREBRAL HEMORRHAGE; cerebral ischemia (BRAIN ISCHEMIA); and CEREBRAL INFARCTION. Cerebral amyloid angiopathy is unrelated to generalized AMYLOIDOSIS. Amyloidogenic peptides in this condition are nearly always the same ones found in ALZHEIMER DISEASE. (from Kumar: Robbins and Cotran: Pathologic Basis of Disease, 7th ed., 2005)
A familial disorder marked by AMYLOID deposits in the walls of small and medium sized blood vessels of CEREBRAL CORTEX and MENINGES.
Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.
A fibrous protein complex that consists of proteins folded into a specific cross beta-pleated sheet structure. This fibrillar structure has been found as an alternative folding pattern for a variety of functional proteins. Deposits of amyloid in the form of AMYLOID PLAQUES are associated with a variety of degenerative diseases. The amyloid structure has also been found in a number of functional proteins that are unrelated to disease.
Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
Accumulations of extracellularly deposited AMYLOID FIBRILS within tissues.
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.
Inflammation of blood vessels within the central nervous system. Primary vasculitis is usually caused by autoimmune or idiopathic factors, while secondary vasculitis is caused by existing disease process. Clinical manifestations are highly variable but include HEADACHE; SEIZURES; behavioral alterations; INTRACRANIAL HEMORRHAGES; TRANSIENT ISCHEMIC ATTACK; and BRAIN INFARCTION. (From Adams et al., Principles of Neurology, 6th ed, pp856-61)
A single-pass type I membrane protein. It is cleaved by AMYLOID PRECURSOR PROTEIN SECRETASES to produce peptides of varying amino acid lengths. A 39-42 amino acid peptide, AMYLOID BETA-PEPTIDES is a principal component of the extracellular amyloid in SENILE PLAQUES.
The arterial blood vessels supplying the CEREBRUM.
An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS.
A homologous group of endogenous CYSTEINE PROTEINASE INHIBITORS. The cystatins inhibit most CYSTEINE ENDOPEPTIDASES such as PAPAIN, and other peptidases which have a sulfhydryl group at the active site.
A form of pneumoconiosis resulting from inhalation of iron in the mining dust or welding fumes.
Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.
A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES.
Abnormal structures located in various parts of the brain and composed of dense arrays of paired helical filaments (neurofilaments and microtubules). These double helical stacks of transverse subunits are twisted into left-handed ribbon-like filaments that likely incorporate the following proteins: (1) the intermediate filaments: medium- and high-molecular-weight neurofilaments; (2) the microtubule-associated proteins map-2 and tau; (3) actin; and (4) UBIQUITINS. As one of the hallmarks of ALZHEIMER DISEASE, the neurofibrillary tangles eventually occupy the whole of the cytoplasm in certain classes of cell in the neocortex, hippocampus, brain stem, and diencephalon. The number of these tangles, as seen in post mortem histology, correlates with the degree of dementia during life. Some studies suggest that tangle antigens leak into the systemic circulation both in the course of normal aging and in cases of Alzheimer disease.
Integral membrane protein of Golgi and endoplasmic reticulum. Its homodimer is an essential component of the gamma-secretase complex that catalyzes the cleavage of membrane proteins such as NOTCH RECEPTORS and AMYLOID BETA-PEPTIDES precursors. PSEN1 mutations cause early-onset ALZHEIMER DISEASE type 3 that may occur as early as 30 years of age in humans.
Pathological conditions of intracranial ARTERIES supplying the CEREBRUM. These diseases often are due to abnormalities or pathological processes in the ANTERIOR CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY; and POSTERIOR CEREBRAL ARTERY.
A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III.
The three membranes that cover the BRAIN and the SPINAL CORD. They are the dura mater, the arachnoid, and the pia mater.
Any of the tubular vessels conveying the blood (arteries, arterioles, capillaries, venules, and veins).
An extracellular cystatin subtype that is abundantly expressed in bodily fluids. It may play a role in the inhibition of interstitial CYSTEINE PROTEASES.
Proteins in the cerebrospinal fluid, normally albumin and globulin present in the ratio of 8 to 1. Increases in protein levels are of diagnostic value in neurological diseases. (Brain and Bannister's Clinical Neurology, 7th ed, p221)
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
Postmortem examination of the body.
An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)
Unsaturated hydrocarbons of the type Cn-H2n, indicated by the suffix -ene. (Grant & Hackh's Chemical Dictionary, 5th ed, p408)
One of three major isoforms of apolipoprotein E. In humans, Apo E2 differs from APOLIPOPROTEIN E3 at one residue 158 where arginine is replaced by cysteine (R158--C). In contrast to Apo E3, Apo E2 displays extremely low binding affinity for LDL receptors (RECEPTORS, LDL) which mediate the internalization and catabolism of lipoprotein particles in liver cells. ApoE2 allelic homozygosity is associated with HYPERLIPOPROTEINEMIA TYPE III.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
The circulation of blood through the BLOOD VESSELS of the BRAIN.
An ACUTE PHASE REACTION protein present in low concentrations in normal sera, but found at higher concentrations in sera of older persons and in patients with AMYLOIDOSIS. It is the circulating precusor of amyloid A protein, which is found deposited in AA type AMYLOID FIBRILS.
The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulchi. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions.
Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.
Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue.
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
The circulation of the BLOOD through the MICROVASCULAR NETWORK.

Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. (1/15)

The dense-cored plaques are considered the pathogenic type of amyloid deposition in Alzheimer's disease brains because of their predominant association with dystrophic neurites. Nevertheless, in > 90% of cases of Alzheimer's disease amyloid is also deposited in cerebral blood vessel walls (congophilic amyloid angiopathy; CAA) but its role in Alzheimer's disease pathogenesis remains enigmatic. Here, we report a family (family GB) in which early-onset Alzheimer's disease was caused by a novel presenilin 1 mutation (L282V). This was unusually severe CAA reminiscent of the Flemish amyloid precursor protein (A692G) mutation we reported previously, which causes Alzheimer's disease and/or cerebral haemorrhages. In family GB, however, the disease presented as typical progressive Alzheimer's disease in the absence of strokes or stroke-like episodes. Similarly, neuroimaging studies and neuropathological examination favoured a degenerative over a vascular dementia. Interestingly, an immunohistochemical study revealed that, similar to causing dense-cored amyloid plaques, CAA also appeared capable of instigating a strong local dystrophic and inflammatory reaction. This was suggested by the observed neuronal loss, the presence of tau- and ubiquitin-positive neurites, micro- and astrogliosis, and complement activation. Together, these data suggest that, like the dense-cored neuritic plaques, CAA might represent a pathogenic lesion that contributes significantly to the progressive neurodegeneration that occurs in Alzheimer's disease.  (+info)

Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant. (2/15)

Amyloid beta-peptide (Abeta) fibril deposition on cerebral vessels produces cerebral amyloid angiopathy that appears in the majority of Alzheimer's disease patients. An early onset of a cerebral amyloid angiopathy variant called hereditary cerebral hemorrhage with amyloidosis of the Dutch type is caused by a point mutation in Abeta yielding Abeta(Glu22-->Gln). The present study addresses the effect of amyloid fibrils from both wild-type and mutated Abeta on vascular cells, as well as the putative protective role of antioxidants on amyloid angiopathy. For this purpose, we studied the cytotoxicity induced by Abeta(1-40 Glu22-->Gln) and Abeta(1-40 wild-type) fibrils on human venule endothelial cells and rat aorta smooth muscle cells. We observed that Abeta(Glu22-->Gln) fibrils are more toxic for vascular cells than the wild-type fibrils. We also evaluated the cytotoxicity of Abeta fibrils bound with acetylcholinesterase (AChE), a common component of amyloid deposits. Abeta(1-40 wild-type)-AChE fibrillar complexes, similar to neuronal cells, resulted in an increased toxicity on vascular cells. Previous reports showing that antioxidants are able to reduce the toxicity of Abeta fibrils on neuronal cells prompted us to test the effect of vitamin E, vitamin C, and 17beta-estradiol on vascular damage induced by Abeta(wild-type) and Abeta(Glu22-->Gln). Our data indicate that vitamin E attenuated significantly the Abeta-mediated cytotoxicity on vascular cells, although 17beta-estradiol and vitamin C failed to inhibit the cytotoxicity induced by Abeta fibrils.  (+info)

RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. (3/15)

Accumulation of amyloid beta-peptide (Abeta) in the central nervous system (CNS) may initiate pathogenic cascades mediating neurovascular and neuronal dysfunctions associated with the development of cerebral beta-amyloidosis and cognitive decline in patients with Alzheimer disease (AD) and with related familial cerebrovascular disorders. Whether Abeta-related pathology in the CNS is reversible or not and what key therapeutic targets are controlling Abeta/amyloid levels in the aging brain remain debatable. In this article, we summarize recent evidence why the receptor for advanced glycation end products and low-density lipoprotein receptor related protein 1 in the vascular CNS barriers are critical for regulation of Abeta homeostasis in the CNS and how altered activities in these 2 receptors at the blood-brain barrier may contribute to the CNS Abeta accumulation resulting in neuroinflammation, disconnect between the cerebral blood flow and metabolism, altered synaptic transmission, neuronal injury, and amyloid deposition into parenchymal and neurovascular lesions. We briefly discuss the potential of advanced glycation end products and low-density lipoprotein receptor related protein 1-based therapeutic strategies to control brain Abeta in animal models of AD and ultimately in patients with AD and related familial cerebrovascular beta-amyloidoses.  (+info)

Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. (4/15)

Cerebral microvascular amyloid-beta (Abeta) protein deposition is emerging as an important contributory factor to neuroinflammation and dementia in Alzheimer's disease and related familial cerebral amyloid angiopathy disorders. In particular, cerebral microvascular amyloid deposition, but not parenchymal amyloid, is more often correlated with dementia. Recently, we generated transgenic mice (Tg-SwDI) expressing the vasculotropic Dutch (E693Q)/Iowa (D694N) mutant human Abeta precursor protein in brain that accumulate abundant cerebral microvascular fibrillar amyloid deposits. In the present study, our aim was to assess how the presence or absence of fibrillar Abeta deposition in the cerebral microvasculature affects neuroinflammation in Tg-SwDI mice. Using Tg-SwDI mice bred onto an apolipoprotein E gene knock-out background, we found a strong reduction of fibrillar cerebral microvascular Abeta deposition, which was accompanied by a sharp decrease in microvascular-associated neuroinflammatory cells and interleukin-1beta levels. Quantitative immunochemical measurements showed that this reduction of the neuroinflammation occurred in the absence of lowering the levels of total Abeta40/Abeta42 or soluble Abeta oligomers in brain. These findings suggest that specifically reducing cerebral microvascular fibrillar Abeta deposition, in the absence of lowering either the total amount of Abeta or soluble Abeta oligomers in brain, may be sufficient to ameliorate microvascular amyloid-associated neuroinflammation.  (+info)

Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. (5/15)

Cerebral vascular amyloid beta-protein (Abeta) deposition, also known as cerebral amyloid angiopathy, is a common pathological feature of Alzheimer's disease. Additionally, several familial forms of cerebral amyloid angiopathy exist including the Dutch (E22Q) and Iowa (D23N) mutations of Abeta. Increasing evidence has associated cerebral microvascular amyloid deposition with neuroinflammation and dementia in these disorders. We recently established a transgenic mouse model (Tg-SwDI) that expresses human vasculotropic Dutch/Iowa mutant amyloid beta-protein precursor in brain. Tg-SwDI mice were shown to develop early-onset deposition of Abeta exhibiting high association with cerebral microvessels. Here we present quantitative temporal analysis showing robust and progressive accumulation of cerebral microvascular fibrillar Abeta accompanied by decreased cerebral vascular densities, the presence of apoptotic cerebral vascular cells, and cerebral vascular cell loss in Tg-SwDI mice. Abundant neuroinflammatory reactive astrocytes and activated microglia strongly associated with the cerebral microvascular fibrillar Abeta deposits. In addition, Tg-SwDI mouse brain exhibited elevated levels of the inflammatory cytokines interleukin-1beta and -6. Together, these studies identify the Tg-SwDI mouse as a unique model to investigate selective accumulation of cerebral microvascular amyloid and the associated neuroinflammation.  (+info)

Inhibition of familial cerebral amyloid angiopathy mutant amyloid beta-protein fibril assembly by myelin basic protein. (6/15)

Deposition of fibrillar amyloid beta-protein (Abeta) in the brain is a prominent pathological feature of Alzheimer disease and related disorders, including familial forms of cerebral amyloid angiopathy (CAA). Mutant forms of Abeta, including Dutch- and Iowa-type Abeta, which are responsible for familial CAA, deposit primarily as fibrillar amyloid along the cerebral vasculature and are either absent or present only as diffuse non-fibrillar plaques in the brain parenchyma. Despite the lack of parenchymal fibril formation in vivo, these CAA mutant Abeta peptides exhibit a markedly increased rate and extent of fibril formation in vitro compared with wild-type Abeta. Based on these conflicting observations, we sought to determine whether brain parenchymal factors that selectively interact with and modulate CAA mutant Abeta fibril assembly exist. Using a combination of immunoaffinity chromatography and mass spectrometry, we identified myelin basic protein (MBP) as a prominent brain parenchymal factor that preferentially binds to CAA mutant Abeta compared with wild-type Abeta. Surface plasmon resonance measurements confirmed that MBP bound more tightly to Dutch/Iowa CAA double mutant Abeta than to wild-type Abeta. Using a combination of biochemical and ultrastructural techniques, we found that MBP inhibited the fibril assembly of CAA mutant Abeta. Together, these findings suggest a possible role for MBP in regulating parenchymal fibrillar Abeta deposition in familial CAA.  (+info)

Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. (7/15)

Inefficient clearance of A beta, caused by impaired blood-brain barrier crossing into the circulation, seems to be a major cause of A beta accumulation in the brain of late-onset Alzheimer's disease patients and hereditary cerebral hemorrhage with amyloidosis Dutch type. We observed association of receptor for advanced glycation end products, CD36, and low-density lipoprotein receptor (LDLR) with cerebral amyloid angiopathy in both Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis Dutch type brains and increased low-density lipoprotein receptor-related protein-1 (LRP-1) expression by perivascular cells in cerebral amyloid angiopathy. We investigated if these A beta receptors are involved in A beta internalization and in A beta-mediated cell death of human cerebrovascular cells and astrocytes. Expression of both the LRP-1 and LDLR by human brain pericytes and leptomeningeal smooth muscle cells, but not by astrocytes, increased on incubation with A beta. Receptor-associated protein specifically inhibited A beta-mediated up-regulation of LRP-1, but not of LDLR, and receptor-associated protein also decreased A beta internalization and A beta-mediated cell death. We conclude that especially LRP-1 and, to a minor extent, LDLR are involved in A beta internalization by and A beta-mediated cell death of cerebral perivascular cells. Although perivascular cells may adapt their A beta internalization capacity to the levels of A beta present, saturated LRP-1/LDLR-mediated uptake of A beta results in degeneration of perivascular cells.  (+info)

E22Q-mutant Abeta peptide (AbetaDutch) increases vascular but reduces parenchymal Abeta deposition. (8/15)

 (+info)

Cerebral amyloid angiopathy (CAA) is a medical condition characterized by the accumulation of beta-amyloid protein in the walls of small to medium-sized blood vessels in the brain. This protein buildup can cause damage to the vessel walls, leading to bleeding (cerebral hemorrhage), cognitive decline, and other neurological symptoms.

CAA is often associated with aging and is a common finding in older adults. It can also be seen in people with Alzheimer's disease and other forms of dementia. The exact cause of CAA is not fully understood, but it is believed to result from the abnormal processing and clearance of beta-amyloid protein in the brain.

The diagnosis of CAA typically involves a combination of clinical evaluation, imaging studies such as MRI or CT scans, and sometimes cerebrospinal fluid analysis. Treatment for CAA is generally supportive and focused on managing symptoms and preventing complications. There are currently no approved disease-modifying treatments for CAA.

Cerebral amyloid angiopathy (CAA), familial type, is a genetic disorder characterized by the buildup of beta-amyloid protein in the walls of blood vessels in the brain. This accumulation can lead to bleeding in the brain (cerebral hemorrhage) and cognitive decline. It is caused by mutations in genes associated with the production or clearance of beta-amyloid, such as the APP, PSEN1, and PSEN2 genes. These genetic mutations are typically inherited in an autosomal dominant manner, meaning that a child has a 50% chance of inheriting the mutation from a parent who carries it. The presence of these mutations leads to an increased production or decreased clearance of beta-amyloid, resulting in its accumulation in the blood vessel walls and subsequent complications.

Amyloid beta-peptides (Aβ) are small protein fragments that are crucially involved in the pathogenesis of Alzheimer's disease. They are derived from a larger transmembrane protein called the amyloid precursor protein (APP) through a series of proteolytic cleavage events.

The two primary forms of Aβ peptides are Aβ40 and Aβ42, which differ in length by two amino acids. While both forms can be harmful, Aβ42 is more prone to aggregation and is considered to be the more pathogenic form. These peptides have the tendency to misfold and accumulate into oligomers, fibrils, and eventually insoluble plaques that deposit in various areas of the brain, most notably the cerebral cortex and hippocampus.

The accumulation of Aβ peptides is believed to initiate a cascade of events leading to neuroinflammation, oxidative stress, synaptic dysfunction, and neuronal death, which are all hallmarks of Alzheimer's disease. Although the exact role of Aβ in the onset and progression of Alzheimer's is still under investigation, it is widely accepted that they play a central part in the development of this debilitating neurodegenerative disorder.

Amyloid is a term used in medicine to describe abnormally folded protein deposits that can accumulate in various tissues and organs of the body. These misfolded proteins can form aggregates known as amyloid fibrils, which have a characteristic beta-pleated sheet structure. Amyloid deposits can be composed of different types of proteins, depending on the specific disease associated with the deposit.

In some cases, amyloid deposits can cause damage to organs and tissues, leading to various clinical symptoms. Some examples of diseases associated with amyloidosis include Alzheimer's disease (where amyloid-beta protein accumulates in the brain), systemic amyloidosis (where amyloid fibrils deposit in various organs such as the heart, kidneys, and liver), and type 2 diabetes (where amyloid deposits form in the pancreas).

It's important to note that not all amyloid deposits are harmful or associated with disease. However, when they do cause problems, treatment typically involves managing the underlying condition that is leading to the abnormal protein accumulation.

A cerebral hemorrhage, also known as an intracranial hemorrhage or intracerebral hemorrhage, is a type of stroke that results from bleeding within the brain tissue. It occurs when a weakened blood vessel bursts and causes localized bleeding in the brain. This bleeding can increase pressure in the skull, damage nearby brain cells, and release toxic substances that further harm brain tissues.

Cerebral hemorrhages are often caused by chronic conditions like hypertension (high blood pressure) or cerebral amyloid angiopathy, which weakens the walls of blood vessels over time. Other potential causes include trauma, aneurysms, arteriovenous malformations, illicit drug use, and brain tumors. Symptoms may include sudden headache, weakness, numbness, difficulty speaking or understanding speech, vision problems, loss of balance, and altered level of consciousness. Immediate medical attention is required to diagnose and manage cerebral hemorrhage through imaging techniques, supportive care, and possible surgical interventions.

Amyloid plaque is a pathological hallmark of several degenerative diseases, including Alzheimer's disease. It refers to extracellular deposits of misfolded proteins that accumulate in various tissues and organs, but are most commonly found in the brain. The main component of these plaques is an abnormally folded form of a protein called amyloid-beta (Aβ). This protein is produced through the normal processing of the amyloid precursor protein (APP), but in amyloid plaques, it aggregates into insoluble fibrils that form the core of the plaque.

The accumulation of amyloid plaques is thought to contribute to neurodegeneration and cognitive decline in Alzheimer's disease and other related disorders. The exact mechanisms by which this occurs are not fully understood, but it is believed that the aggregation of Aβ into plaques leads to the disruption of neuronal function and viability, as well as the activation of inflammatory responses that can further damage brain tissue.

It's important to note that while amyloid plaques are a key feature of Alzheimer's disease, they are not exclusive to this condition. Amyloid plaques have also been found in other neurodegenerative disorders, as well as in some normal aging brains, although their significance in these contexts is less clear.

Alzheimer's disease is a progressive disorder that causes brain cells to waste away (degenerate) and die. It's the most common cause of dementia — a continuous decline in thinking, behavioral and social skills that disrupts a person's ability to function independently.

The early signs of the disease include forgetting recent events or conversations. As the disease progresses, a person with Alzheimer's disease will develop severe memory impairment and lose the ability to carry out everyday tasks.

Currently, there's no cure for Alzheimer's disease. However, treatments can temporarily slow the worsening of dementia symptoms and improve quality of life.

Amyloidosis is a medical condition characterized by the abnormal accumulation of insoluble proteins called amyloid in various tissues and organs throughout the body. These misfolded protein deposits can disrupt the normal function of affected organs, leading to a range of symptoms depending on the location and extent of the amyloid deposition.

There are different types of amyloidosis, classified based on the specific proteins involved:

1. Primary (AL) Amyloidosis: This is the most common form, accounting for around 80% of cases. It results from the overproduction and misfolding of immunoglobulin light chains, typically by clonal plasma cells in the bone marrow. The amyloid deposits can affect various organs, including the heart, kidneys, liver, and nervous system.
2. Secondary (AA) Amyloidosis: This form is associated with chronic inflammatory diseases, such as rheumatoid arthritis, tuberculosis, or familial Mediterranean fever. The amyloid fibrils are composed of serum amyloid A protein (SAA), an acute-phase reactant produced during the inflammatory response. The kidneys are commonly affected in this type of amyloidosis.
3. Hereditary or Familial Amyloidosis: These forms are caused by genetic mutations that result in the production of abnormal proteins prone to misfolding and amyloid formation. Examples include transthyretin (TTR) amyloidosis, fibrinogen amyloidosis, and apolipoprotein AI amyloidosis. These forms can affect various organs, including the heart, nerves, and kidneys.
4. Dialysis-Related Amyloidosis: This form is seen in patients undergoing long-term dialysis for chronic kidney disease. The amyloid fibrils are composed of beta-2 microglobulin, a protein that accumulates due to impaired clearance during dialysis. The joints and bones are commonly affected in this type of amyloidosis.

The diagnosis of amyloidosis typically involves a combination of clinical evaluation, imaging studies, and tissue biopsy with the demonstration of amyloid deposition using special stains (e.g., Congo red). Treatment depends on the specific type and extent of organ involvement and may include supportive care, medications to target the underlying cause (e.g., chemotherapy, immunomodulatory agents), and organ transplantation in some cases.

The brain is the central organ of the nervous system, responsible for receiving and processing sensory information, regulating vital functions, and controlling behavior, movement, and cognition. It is divided into several distinct regions, each with specific functions:

1. Cerebrum: The largest part of the brain, responsible for higher cognitive functions such as thinking, learning, memory, language, and perception. It is divided into two hemispheres, each controlling the opposite side of the body.
2. Cerebellum: Located at the back of the brain, it is responsible for coordinating muscle movements, maintaining balance, and fine-tuning motor skills.
3. Brainstem: Connects the cerebrum and cerebellum to the spinal cord, controlling vital functions such as breathing, heart rate, and blood pressure. It also serves as a relay center for sensory information and motor commands between the brain and the rest of the body.
4. Diencephalon: A region that includes the thalamus (a major sensory relay station) and hypothalamus (regulates hormones, temperature, hunger, thirst, and sleep).
5. Limbic system: A group of structures involved in emotional processing, memory formation, and motivation, including the hippocampus, amygdala, and cingulate gyrus.

The brain is composed of billions of interconnected neurons that communicate through electrical and chemical signals. It is protected by the skull and surrounded by three layers of membranes called meninges, as well as cerebrospinal fluid that provides cushioning and nutrients.

Vasculitis, Central Nervous System (CNS), refers to a group of disorders characterized by inflammation of blood vessels within the brain and/or spinal cord. This inflammation can cause damage to the blood vessel walls, leading to narrowing, blocking or weakening of the vessels, and in some cases, formation of aneurysms or rupture of the vessels.

The causes of CNS vasculitis are varied and can include infections, autoimmune diseases, medications, and unknown factors. The symptoms of CNS vasculitis depend on the severity and location of the inflammation, and may include headache, seizures, stroke-like symptoms (such as weakness or numbness in the face, arms, or legs), cognitive changes, and in severe cases, coma.

Diagnosis of CNS vasculitis typically involves a combination of clinical evaluation, imaging studies (such as MRI or angiography), and laboratory tests (including blood tests and analysis of cerebrospinal fluid). Treatment may involve corticosteroids, immunosuppressive medications, and/or other therapies aimed at reducing inflammation and preventing further damage to the blood vessels.

The Amyloid Beta-Protein Precursor (AβPP) is a type of transmembrane protein that is widely expressed in various tissues and organs, including the brain. It plays a crucial role in normal physiological processes, such as neuronal development, synaptic plasticity, and repair.

AβPP undergoes proteolytic processing by enzymes called secretases, resulting in the production of several protein fragments, including the amyloid-beta (Aβ) peptide. Aβ is a small peptide that can aggregate and form insoluble fibrils, which are the main component of amyloid plaques found in the brains of patients with Alzheimer's disease (AD).

The accumulation of Aβ plaques is believed to contribute to the neurodegeneration and cognitive decline observed in AD. Therefore, AβPP and its proteolytic processing have been the focus of extensive research aimed at understanding the pathogenesis of AD and developing potential therapies.

Cerebral arteries refer to the blood vessels that supply oxygenated blood to the brain. These arteries branch off from the internal carotid arteries and the vertebral arteries, which combine to form the basilar artery. The major cerebral arteries include:

1. Anterior cerebral artery (ACA): This artery supplies blood to the frontal lobes of the brain, including the motor and sensory cortices responsible for movement and sensation in the lower limbs.
2. Middle cerebral artery (MCA): The MCA is the largest of the cerebral arteries and supplies blood to the lateral surface of the brain, including the temporal, parietal, and frontal lobes. It is responsible for providing blood to areas involved in motor function, sensory perception, speech, memory, and vision.
3. Posterior cerebral artery (PCA): The PCA supplies blood to the occipital lobe, which is responsible for visual processing, as well as parts of the temporal and parietal lobes.
4. Anterior communicating artery (ACoA) and posterior communicating arteries (PComAs): These are small arteries that connect the major cerebral arteries, forming an important circulatory network called the Circle of Willis. The ACoA connects the two ACAs, while the PComAs connect the ICA with the PCA and the basilar artery.

These cerebral arteries play a crucial role in maintaining proper brain function by delivering oxygenated blood to various regions of the brain. Any damage or obstruction to these arteries can lead to serious neurological conditions, such as strokes or transient ischemic attacks (TIAs).

Congo Red is a synthetic diazo dye that is commonly used in histology and pathology for stainings and tests. It is particularly useful in identifying amyloid deposits in tissues, which are associated with various diseases such as Alzheimer's disease, type 2 diabetes, and systemic amyloidosis.

When Congo Red binds to amyloid fibrils, it exhibits a characteristic apple-green birefringence under polarized light microscopy. Additionally, Congo Red stained amyloid deposits show a shift in their emission spectrum when excited with circularly polarized light, a phenomenon known as dichroism. These properties make Congo Red a valuable tool for the diagnosis and study of amyloidosis and other protein misfolding disorders.

It is important to note that Congo Red staining should be performed with care, as it can be toxic and carcinogenic if not handled properly.

Cystatins are a group of proteins that inhibit cysteine proteases, which are enzymes that break down other proteins. Cystatins are found in various biological fluids and tissues, including tears, saliva, seminal plasma, and urine. They play an important role in regulating protein catabolism and protecting cells from excessive protease activity. There are three main types of cystatins: type 1 (cystatin C), type 2 (cystatin M, cystatin N, and fetuin), and type 3 (kininogens). Abnormal levels of cystatins have been associated with various pathological conditions, such as cancer, neurodegenerative diseases, and inflammatory disorders.

Siderosis is a medical condition characterized by the abnormal accumulation of iron in various tissues and organs, most commonly in the lungs. This occurs due to the repeated inhalation of iron-containing dusts or fumes, which can result from certain industrial processes such as welding, mining, or smelting.

In the lungs, this iron deposit can lead to inflammation and fibrosis, potentially causing symptoms like coughing, shortness of breath, and decreased lung function. It is important to note that siderosis itself is not contagious or cancerous, but there may be an increased risk for lung cancer in individuals with severe and prolonged exposure to iron-containing particles.

While siderosis is generally non-reversible, the progression of symptoms can often be managed through medical interventions and environmental modifications to reduce further exposure to iron-containing dusts or fumes.

Intracranial hemorrhage (ICH) is a type of stroke caused by bleeding within the brain or its surrounding tissues. It's a serious medical emergency that requires immediate attention and treatment. The bleeding can occur in various locations:

1. Epidural hematoma: Bleeding between the dura mater (the outermost protective covering of the brain) and the skull. This is often caused by trauma, such as a head injury.
2. Subdural hematoma: Bleeding between the dura mater and the brain's surface, which can also be caused by trauma.
3. Subarachnoid hemorrhage: Bleeding in the subarachnoid space, which is filled with cerebrospinal fluid (CSF) and surrounds the brain. This type of ICH is commonly caused by the rupture of an intracranial aneurysm or arteriovenous malformation.
4. Intraparenchymal hemorrhage: Bleeding within the brain tissue itself, which can be caused by hypertension (high blood pressure), amyloid angiopathy, or trauma.
5. Intraventricular hemorrhage: Bleeding into the brain's ventricular system, which contains CSF and communicates with the subarachnoid space. This type of ICH is often seen in premature infants but can also be caused by head trauma or aneurysm rupture in adults.

Symptoms of intracranial hemorrhage may include sudden severe headache, vomiting, altered consciousness, confusion, seizures, weakness, numbness, or paralysis on one side of the body, vision changes, or difficulty speaking or understanding speech. Rapid diagnosis and treatment are crucial to prevent further brain damage and potential long-term disabilities or death.

Apolipoprotein E (APOE) is a gene that provides instructions for making a protein involved in the metabolism of fats called lipids. One variant of this gene, APOE4, is associated with an increased risk of developing Alzheimer's disease and other forms of dementia.

The APOE4 allele (variant) is less efficient at clearing beta-amyloid protein, a component of the amyloid plaques found in the brains of people with Alzheimer's disease. This can lead to an accumulation of beta-amyloid and an increased risk of developing Alzheimer's disease.

It is important to note that having one or two copies of the APOE4 allele does not mean that a person will definitely develop Alzheimer's disease, but it does increase the risk. Other factors, such as age, family history, and the presence of other genetic variants, also contribute to the development of this complex disorder.

Neurofibrillary tangles are a pathological hallmark of several neurodegenerative disorders, most notably Alzheimer's disease. They are intracellular inclusions composed of abnormally phosphorylated and aggregated tau protein, which forms paired helical filaments. These tangles accumulate within the neurons, leading to their dysfunction and eventual death. The presence and density of neurofibrillary tangles are strongly associated with cognitive decline and disease progression in Alzheimer's disease and other related dementias.

Presenilin-1 (PSEN1) is a gene that provides instructions for making one part of an enzyme complex called gamma-secretase. This enzyme is involved in the breakdown of certain proteins, most notably the amyloid precursor protein (APP), into smaller fragments called peptides. One of these peptides, called beta-amyloid, can accumulate and form clumps called plaques, which are a characteristic feature of Alzheimer's disease.

Mutations in the PSEN1 gene have been identified as a major cause of early-onset familial Alzheimer's disease (FAD), a rare, inherited form of the disorder that usually develops before age 65. These mutations result in an abnormal gamma-secretase enzyme that produces more toxic beta-amyloid peptides and fewer harmless ones, leading to the formation of amyloid plaques and neurodegeneration.

It's important to note that while mutations in PSEN1 are associated with early-onset FAD, most cases of Alzheimer's disease are sporadic and develop later in life, typically after age 65. The role of PSEN1 and other genes associated with FAD in the more common, late-onset form of Alzheimer's is still being researched.

Cerebral arterial diseases refer to conditions that affect the blood vessels supplying the brain. These diseases can result in reduced blood flow, blockages, or bleeding in the brain. The most common cerebral arterial diseases include:

1. Atherosclerosis: A buildup of plaque made up of fat, cholesterol, and other substances in the inner lining of an artery, which can lead to narrowing or blockage of the artery.
2. Embolism: A blood clot or other particle that forms elsewhere in the body and travels to the brain, where it blocks a cerebral artery.
3. Thrombosis: The formation of a blood clot within a cerebral artery.
4. Aneurysm: A weakened area in the wall of an artery that bulges out and can rupture, causing bleeding in the brain.
5. Arteriovenous malformation (AVM): An abnormal tangle of blood vessels in the brain that can cause bleeding or reduced blood flow to surrounding tissue.
6. Vasculitis: Inflammation of the blood vessels in the brain, which can lead to narrowing, blockage, or weakening of the vessel walls.

These conditions can lead to serious complications such as stroke, transient ischemic attack (TIA), or vascular dementia. Treatment options include medications, surgery, and lifestyle changes to manage risk factors.

Apolipoprotein E (ApoE) is a protein involved in the metabolism of lipids, particularly cholesterol. It is produced primarily by the liver and is a component of several types of lipoproteins, including very low-density lipoproteins (VLDL) and high-density lipoproteins (HDL).

ApoE plays a crucial role in the transport and uptake of lipids in the body. It binds to specific receptors on cell surfaces, facilitating the delivery of lipids to cells for energy metabolism or storage. ApoE also helps to clear cholesterol from the bloodstream and is involved in the repair and maintenance of tissues.

There are three major isoforms of ApoE, designated ApoE2, ApoE3, and ApoE4, which differ from each other by only a few amino acids. These genetic variations can have significant effects on an individual's risk for developing certain diseases, particularly cardiovascular disease and Alzheimer's disease. For example, individuals who inherit the ApoE4 allele have an increased risk of developing Alzheimer's disease, while those with the ApoE2 allele may have a reduced risk.

In summary, Apolipoprotein E is a protein involved in lipid metabolism and transport, and genetic variations in this protein can influence an individual's risk for certain diseases.

The meninges are the protective membranes that cover the brain and spinal cord. They consist of three layers: the dura mater (the outermost, toughest layer), the arachnoid mater (middle layer), and the pia mater (the innermost, delicate layer). These membranes provide protection and support to the central nervous system, and contain blood vessels that supply nutrients and remove waste products. Inflammation or infection of the meninges is called meningitis, which can be a serious medical condition requiring prompt treatment.

Blood vessels are the part of the circulatory system that transport blood throughout the body. They form a network of tubes that carry blood to and from the heart, lungs, and other organs. The main types of blood vessels are arteries, veins, and capillaries. Arteries carry oxygenated blood away from the heart to the rest of the body, while veins return deoxygenated blood back to the heart. Capillaries connect arteries and veins and facilitate the exchange of oxygen, nutrients, and waste materials between the blood and the body's tissues.

Cystatin C is a protein produced by many cells in the body, including all types of nucleated cells. It is a member of the cysteine protease inhibitor family and functions as an endogenous inhibitor of cathepsins, which are proteases involved in various physiological and pathological processes such as extracellular matrix degradation, antigen presentation, and cell death.

Cystatin C is freely filtered by the glomeruli in the kidneys and almost completely reabsorbed and catabolized by the proximal tubules. Therefore, its serum concentration is a reliable marker of glomerular filtration rate (GFR) and can be used to estimate kidney function.

Increased levels of cystatin C in the blood may indicate impaired kidney function or kidney disease, while decreased levels are less common and may be associated with hyperfiltration or overproduction of cystatin C. Measuring cystatin C levels can complement or supplement traditional methods for assessing kidney function, such as estimating GFR based on serum creatinine levels.

Cerebrospinal fluid (CSF) proteins refer to the proteins present in the cerebrospinal fluid, which is a clear, colorless fluid that surrounds and protects the brain and spinal cord. The protein concentration in the CSF is much lower than that in the blood, and it contains a specific set of proteins that are produced by the brain, spinal cord, and associated tissues.

The normal range for CSF protein levels is typically between 15-45 mg/dL, although this can vary slightly depending on the laboratory's reference range. An elevation in CSF protein levels may indicate the presence of neurological disorders such as meningitis, encephalitis, multiple sclerosis, or Guillain-Barre syndrome. Additionally, certain conditions such as spinal cord injury, brain tumors, or neurodegenerative diseases can also cause an increase in CSF protein levels.

Therefore, measuring CSF protein levels is an important diagnostic tool for neurologists to evaluate various neurological disorders and monitor disease progression. However, it's essential to interpret the results of CSF protein tests in conjunction with other clinical findings and laboratory test results to make an accurate diagnosis.

Transgenic mice are genetically modified rodents that have incorporated foreign DNA (exogenous DNA) into their own genome. This is typically done through the use of recombinant DNA technology, where a specific gene or genetic sequence of interest is isolated and then introduced into the mouse embryo. The resulting transgenic mice can then express the protein encoded by the foreign gene, allowing researchers to study its function in a living organism.

The process of creating transgenic mice usually involves microinjecting the exogenous DNA into the pronucleus of a fertilized egg, which is then implanted into a surrogate mother. The offspring that result from this procedure are screened for the presence of the foreign DNA, and those that carry the desired genetic modification are used to establish a transgenic mouse line.

Transgenic mice have been widely used in biomedical research to model human diseases, study gene function, and test new therapies. They provide a valuable tool for understanding complex biological processes and developing new treatments for a variety of medical conditions.

Cerebrovascular disorders are a group of medical conditions that affect the blood vessels of the brain. These disorders can be caused by narrowing, blockage, or rupture of the blood vessels, leading to decreased blood flow and oxygen supply to the brain. The most common types of cerebrovascular disorders include:

1. Stroke: A stroke occurs when a blood vessel in the brain becomes blocked or bursts, causing a lack of oxygen and nutrients to reach brain cells. This can lead to permanent damage or death of brain tissue.
2. Transient ischemic attack (TIA): Also known as a "mini-stroke," a TIA occurs when blood flow to the brain is temporarily blocked, often by a blood clot. Symptoms may last only a few minutes to a few hours and typically resolve on their own. However, a TIA is a serious warning sign that a full-blown stroke may occur in the future.
3. Aneurysm: An aneurysm is a weakened or bulging area in the wall of a blood vessel. If left untreated, an aneurysm can rupture and cause bleeding in the brain.
4. Arteriovenous malformation (AVM): An AVM is a tangled mass of abnormal blood vessels that connect arteries and veins. This can lead to bleeding in the brain or stroke.
5. Carotid stenosis: Carotid stenosis occurs when the carotid arteries, which supply blood to the brain, become narrowed or blocked due to plaque buildup. This can increase the risk of stroke.
6. Vertebrobasilar insufficiency: This condition occurs when the vertebral and basilar arteries, which supply blood to the back of the brain, become narrowed or blocked. This can lead to symptoms such as dizziness, vertigo, and difficulty swallowing.

Cerebrovascular disorders are a leading cause of disability and death worldwide. Risk factors for these conditions include age, high blood pressure, smoking, diabetes, high cholesterol, and family history. Treatment may involve medications, surgery, or lifestyle changes to reduce the risk of further complications.

Medical Definition:

Magnetic Resonance Imaging (MRI) is a non-invasive diagnostic imaging technique that uses a strong magnetic field and radio waves to create detailed cross-sectional or three-dimensional images of the internal structures of the body. The patient lies within a large, cylindrical magnet, and the scanner detects changes in the direction of the magnetic field caused by protons in the body. These changes are then converted into detailed images that help medical professionals to diagnose and monitor various medical conditions, such as tumors, injuries, or diseases affecting the brain, spinal cord, heart, blood vessels, joints, and other internal organs. MRI does not use radiation like computed tomography (CT) scans.

Dementia is a broad term that describes a decline in cognitive functioning, including memory, language, problem-solving, and judgment, severe enough to interfere with daily life. It is not a specific disease but rather a group of symptoms that may be caused by various underlying diseases or conditions. Alzheimer's disease is the most common cause of dementia, accounting for 60-80% of cases. Other causes include vascular dementia, Lewy body dementia, frontotemporal dementia, and Huntington's disease.

The symptoms of dementia can vary widely depending on the cause and the specific areas of the brain that are affected. However, common early signs of dementia may include:

* Memory loss that affects daily life
* Difficulty with familiar tasks
* Problems with language or communication
* Difficulty with visual and spatial abilities
* Misplacing things and unable to retrace steps
* Decreased or poor judgment
* Withdrawal from work or social activities
* Changes in mood or behavior

Dementia is a progressive condition, meaning that symptoms will gradually worsen over time. While there is currently no cure for dementia, early diagnosis and treatment can help slow the progression of the disease and improve quality of life for those affected.

An autopsy, also known as a post-mortem examination or obduction, is a medical procedure in which a qualified professional (usually a pathologist) examines a deceased person's body to determine the cause and manner of death. This process may involve various investigative techniques, such as incisions to study internal organs, tissue sampling, microscopic examination, toxicology testing, and other laboratory analyses. The primary purpose of an autopsy is to gather objective evidence about the medical conditions and factors contributing to the individual's demise, which can be essential for legal, insurance, or public health purposes. Additionally, autopsies can provide valuable insights into disease processes and aid in advancing medical knowledge.

Vascular dementia is a type of dementia that is caused by damage to the blood vessels that supply blood to the brain. This damage can result from conditions such as stroke, chronic high blood pressure, diabetes, or other diseases that affect the circulatory system. The interruption in blood flow to the brain can lead to damaged or dead brain cells, which can impair cognitive function and cause symptoms similar to those seen in other types of dementia, such as Alzheimer's disease.

The symptoms of vascular dementia can vary depending on the severity and location of the damage to the blood vessels. However, common symptoms include difficulties with memory, attention, and decision-making; problems with language and speech; changes in mood or behavior; and difficulty walking or performing other physical tasks. Vascular dementia is typically a progressive condition, meaning that the symptoms tend to worsen over time.

It's important to note that vascular dementia can coexist with other types of dementia, such as Alzheimer's disease, and this is known as mixed dementia. Proper diagnosis and management of underlying medical conditions that contribute to vascular dementia can help slow down the progression of cognitive decline and improve quality of life for individuals living with this condition.

Alkenes are unsaturated hydrocarbons that contain at least one carbon-carbon double bond in their molecular structure. The general chemical formula for alkenes is CnH2n, where n represents the number of carbon atoms in the molecule.

The double bond in alkenes can undergo various reactions, such as addition reactions, where different types of molecules can add across the double bond to form new compounds. The relative position of the double bond in the carbon chain and the presence of substituents on the carbon atoms can affect the physical and chemical properties of alkenes.

Alkenes are important industrial chemicals and are used as starting materials for the synthesis of a wide range of products, including plastics, resins, fibers, and other chemicals. They are also found in nature, occurring in some plants and animals, and can be produced by certain types of bacteria through fermentation processes.

Apolipoprotein E2 (ApoE2) is one of the three major isoforms of the apolipoprotein E (ApoE) protein, which is a component of lipoproteins that are involved in the transport and metabolism of cholesterol and other fats in the body. ApoE is produced by the APOE gene, which has three common alleles: ε2, ε3, and ε4.

The ApoE2 protein is encoded by the ε2 allele of the APOE gene. Compared to the other two isoforms (ApoE3 and ApoE4), ApoE2 has a different amino acid at position 112, where it has a cysteine instead of an arginine. This difference affects the protein's ability to interact with other molecules involved in lipid metabolism, such as the low-density lipoprotein receptor (LDLR).

Individuals who inherit two copies of the ε2 allele (ε2/ε2) have a higher risk of developing type III hyperlipoproteinemia, also known as dysbetalipoproteinemia, which is characterized by elevated levels of cholesterol and triglycerides in the blood due to impaired clearance of remnant lipoproteins. However, not all people with the ε2/ε2 genotype develop type III hyperlipoproteinemia, and other genetic and environmental factors may contribute to the development of this condition.

It's worth noting that having one or two copies of the ε2 allele has been associated with a reduced risk of developing Alzheimer's disease, although the mechanism by which ApoE2 protects against Alzheimer's is not fully understood.

A peptide fragment is a short chain of amino acids that is derived from a larger peptide or protein through various biological or chemical processes. These fragments can result from the natural breakdown of proteins in the body during regular physiological processes, such as digestion, or they can be produced experimentally in a laboratory setting for research or therapeutic purposes.

Peptide fragments are often used in research to map the structure and function of larger peptides and proteins, as well as to study their interactions with other molecules. In some cases, peptide fragments may also have biological activity of their own and can be developed into drugs or diagnostic tools. For example, certain peptide fragments derived from hormones or neurotransmitters may bind to receptors in the body and mimic or block the effects of the full-length molecule.

Cerebrovascular circulation refers to the network of blood vessels that supply oxygenated blood and nutrients to the brain tissue, and remove waste products. It includes the internal carotid arteries, vertebral arteries, circle of Willis, and the intracranial arteries that branch off from them.

The internal carotid arteries and vertebral arteries merge to form the circle of Willis, a polygonal network of vessels located at the base of the brain. The anterior cerebral artery, middle cerebral artery, posterior cerebral artery, and communicating arteries are the major vessels that branch off from the circle of Willis and supply blood to different regions of the brain.

Interruptions or abnormalities in the cerebrovascular circulation can lead to various neurological conditions such as stroke, transient ischemic attack (TIA), and vascular dementia.

Serum Amyloid A (SAA) protein is an acute phase protein produced primarily in the liver, although it can also be produced by other cells in response to inflammation. It is a member of the apolipoprotein family and is found in high-density lipoproteins (HDL) in the blood. SAA protein levels increase rapidly during the acute phase response to infection, trauma, or tissue damage, making it a useful biomarker for inflammation.

In addition to its role as an acute phase protein, SAA has been implicated in several disease processes, including atherosclerosis and amyloidosis. In amyloidosis, SAA can form insoluble fibrils that deposit in various tissues, leading to organ dysfunction. There are four subtypes of SAA in humans (SAA1, SAA2, SAA3, and SAA4), with SAA1 and SAA2 being the most responsive to inflammatory stimuli.

The cerebral cortex is the outermost layer of the brain, characterized by its intricate folded structure and wrinkled appearance. It is a region of great importance as it plays a key role in higher cognitive functions such as perception, consciousness, thought, memory, language, and attention. The cerebral cortex is divided into two hemispheres, each containing four lobes: the frontal, parietal, temporal, and occipital lobes. These areas are responsible for different functions, with some regions specializing in sensory processing while others are involved in motor control or associative functions. The cerebral cortex is composed of gray matter, which contains neuronal cell bodies, and is covered by a layer of white matter that consists mainly of myelinated nerve fibers.

Brain diseases, also known as neurological disorders, refer to a wide range of conditions that affect the brain and nervous system. These diseases can be caused by various factors such as genetics, infections, injuries, degeneration, or structural abnormalities. They can affect different parts of the brain, leading to a variety of symptoms and complications.

Some examples of brain diseases include:

1. Alzheimer's disease - a progressive degenerative disorder that affects memory and cognitive function.
2. Parkinson's disease - a movement disorder characterized by tremors, stiffness, and difficulty with coordination and balance.
3. Multiple sclerosis - a chronic autoimmune disease that affects the nervous system and can cause a range of symptoms such as vision loss, muscle weakness, and cognitive impairment.
4. Epilepsy - a neurological disorder characterized by recurrent seizures.
5. Brain tumors - abnormal growths in the brain that can be benign or malignant.
6. Stroke - a sudden interruption of blood flow to the brain, which can cause paralysis, speech difficulties, and other neurological symptoms.
7. Meningitis - an infection of the membranes surrounding the brain and spinal cord.
8. Encephalitis - an inflammation of the brain that can be caused by viruses, bacteria, or autoimmune disorders.
9. Huntington's disease - a genetic disorder that affects muscle coordination, cognitive function, and mental health.
10. Migraine - a neurological condition characterized by severe headaches, often accompanied by nausea, vomiting, and sensitivity to light and sound.

Brain diseases can range from mild to severe and may be treatable or incurable. They can affect people of all ages and backgrounds, and early diagnosis and treatment are essential for improving outcomes and quality of life.

The Blood-Brain Barrier (BBB) is a highly specialized, selective interface between the central nervous system (CNS) and the circulating blood. It is formed by unique endothelial cells that line the brain's capillaries, along with tight junctions, astrocytic foot processes, and pericytes, which together restrict the passage of substances from the bloodstream into the CNS. This barrier serves to protect the brain from harmful agents and maintain a stable environment for proper neural function. However, it also poses a challenge in delivering therapeutics to the CNS, as most large and hydrophilic molecules cannot cross the BBB.

Aging is a complex, progressive and inevitable process of bodily changes over time, characterized by the accumulation of cellular damage and degenerative changes that eventually lead to increased vulnerability to disease and death. It involves various biological, genetic, environmental, and lifestyle factors that contribute to the decline in physical and mental functions. The medical field studies aging through the discipline of gerontology, which aims to understand the underlying mechanisms of aging and develop interventions to promote healthy aging and extend the human healthspan.

A fatal outcome is a term used in medical context to describe a situation where a disease, injury, or illness results in the death of an individual. It is the most severe and unfortunate possible outcome of any medical condition, and is often used as a measure of the severity and prognosis of various diseases and injuries. In clinical trials and research, fatal outcome may be used as an endpoint to evaluate the effectiveness and safety of different treatments or interventions.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Microcirculation is the circulation of blood in the smallest blood vessels, including arterioles, venules, and capillaries. It's responsible for the delivery of oxygen and nutrients to the tissues and the removal of waste products. The microcirculation plays a crucial role in maintaining tissue homeostasis and is regulated by various physiological mechanisms such as autonomic nervous system activity, local metabolic factors, and hormones.

Impairment of microcirculation can lead to tissue hypoxia, inflammation, and organ dysfunction, which are common features in several diseases, including diabetes, hypertension, sepsis, and ischemia-reperfusion injury. Therefore, understanding the structure and function of the microcirculation is essential for developing new therapeutic strategies to treat these conditions.

Hereditary cerebral amyloid angiopathy is a condition that can cause a progressive loss of intellectual function (dementia), ... Two types of hereditary cerebral amyloid angiopathy, known as familial British dementia and familial Danish dementia, are ... medlineplus.gov/genetics/condition/hereditary-cerebral-amyloid-angiopathy/ Hereditary cerebral amyloid angiopathy. ... Genetic Testing Registry: Cerebral amyloid angiopathy, APP-related *Genetic Testing Registry: Hereditary cerebral amyloid ...
Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimers dementias. Journal of ... Extracellular vesicles from human pancreatic islets suppress human islet amyloid polypeptide amyloid formation. Proc Natl Acad ... "Beta-Amyloid Precursor Protein-B Is Essential for Mauthner Cell Development in the Zebrafish in a Notch-Dependent Manner." Dev ... The zebrafish amyloid precursor protein-b is required for motor neuron guidance and synapse formation. Abramsson A, Kettunen P ...
Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimer s dementias ...
"Sporadic and familial cerebral amyloid angiopathies". Brain Pathology (Zurich, Switzerland). 12 (3): 343-357. doi:10.1111/j. ... Cerebral amyloid angiopathy (CAA) is a form of angiopathy in which amyloid beta peptide deposits in the walls of small to ... The aim in cerebral amyloid angiopathy is to treat the symptoms, as there is no current cure. Physical, occupational and/or ... Cerebral amyloid angiopathy can be presented with lobar intracerebral hemorrhage or microbleeds in the brain. The bleeding ...
... in APP are associated with familial forms of early onset Alzheimers disease as well as with Cerebral Amyloid Angiopathy (CAA ... APP encodes amyloid precursor protein, a transmembrane protein which is cleaved to form amyloidogenic Aβ peptides. Mutations ... MAPT mutations are not linked to familial forms of AD, but can cause frontotemporal dementia (FTD) and several other ...
... of the cerebral cortex and the leptomeninges. It is a component of any disorder in which amyloid is deposited in the brain, and ... refers to the deposition of β-amyloid in the media and adventitia of small and mid-sized arteries (and, less frequently, veins ... Familial forms of CAA are associated with hemorrhage at younger ages, by the third or fourth decade in the Icelandic form and ... The Boston Cerebral Amyloid Angiopathy Group has elaborated guidelines for the diagnosis of cerebral amyloid angiopathy (CAA) ...
Cerebral Amyloid Angiopathy, Ataxia,Arthritis,Amyotrophic Lateral Scoliosis,Autism,Fibromyalgia,Fluoroquinolone ... HypertensionFatal Familial Insomnia Factor V Leiden Mutation ,Epilepsy Dupuytrens disease,Desmoplastic small-round-cell tumor ...
Cerebral Amyloid Angiopathy, Ataxia,Arthritis,Amyotrophic Lateral Scoliosis,Autism,Fibromyalgia,Fluoroquinolone ... HypertensionFatal Familial Insomnia Factor V Leiden Mutation ,Epilepsy Dupuytrens disease,Desmoplastic small-round-cell tumor ...
Cerebral Amyloid Angiopathy, Familial 1 0 Telangiectasia, Hereditary Hemorrhagic 1 0 Toxoplasmosis 1 0 ...
Cerebral Amyloid Angiopathy, Familial 3 genes has been reported with Cerebral Amyloid Angiopathy, Familial ...
Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants. CHMP2B. Dementia, familial, nonspecific; ... Cerebral amyloid angiopathy, PRNP-related;. Creutzfeldt-Jakob disease; Huntington disease-like 1; Insomnia, fatal familial;. ... Familial Lipoprotein Lipase Deficiency. *Familial Thoracic Aortic Aneurysm and Dissection and Related Syndromes NGS panel *List ... Familial Hemiplegic Migraine NGS panel *List of diseases covered by Familial Hemiplegic Migraine NGS panel ...
... a hereditary cerebral small vessel disease (SVD) characterized by the aggregation of the Notch3 extracellular domain. We found ... CAA is characterized by the aggregation of amyloid-β (Aβ) peptides and formation of Aβ deposits in the brain vasculature ... including a patient with hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), and of AD cases without ... Cerebral amyloid angiopathy (CAA) is an age-related condition and a major cause of intracerebral hemorrhage and cognitive ...
Cerebral amyloid angiopathy is age-dependent and may be a cause of lobar intraparenchymal hemorrhage. Sometimes, CAA may occur ... or as a certain familial syndrome. CAA is characterized by the deposition of congophilic material in small to medium-sized ... Cerebral amyloid angiopathy (CAA), although usually asymptomatic, is an important cause of primary lobar intracerebral ... Case 1, image 2: There are amyloid deposits in small to medium-sized blood vessels of the brain. The deposits weaken the blood ...
Patients develop cerebral hemorrhage because of the severe cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare ... Defects in APP are the cause of Alzheimer disease type 1 (AD1) [MIM:104300]. AD1 is a familial early-onset form of Alzheimer ... Defects in APP are the cause of cerebral amyloid angiopathy APP-related (CAA-APP) [MIM:605714]. A hereditary localized ... It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by ...
Erratum: Senile plaques in cerebral amyloid angiopathy show accumulation of amyloid precursor protein without cytoskeletal ... Codistribution of amyloid beta plaques and spongiform degeneration in familial Creutzfeldt-Jakob disease with the E200K-129M ... Creutzfeldt-Jakob disease and cerebral amyloid angiopathy. Acta Neuropathologica. 88: 106-11. PMID 7941967 DOI: 10.1007/ ... Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. Brain Pathology ...
Cerebral Amyloid Angiopathy, Ataxia,Arthritis,Amyotrophic Lateral Scoliosis,Fibromyalgia,Fluoroquinolone Toxicity. Syndrome ... siva.Fatal Familial Insomnia Factor V Leiden Mutation ,Epilepsy Dupuytrens disease,Desmoplastic small-round-cell tumor ...
ABri/Cerebral amyloid angiopathy Aβ/Alzheimers disease Kidney AApoA1+AFib+ALys/Familial renal Skin Primary cutaneous ... ABri/Cerebral amyloid angiopathy Aβ/Alzheimers disease Kidney AApoA1+AFib+ALys/Familial renal Skin Primary cutaneous ... ABri/Cerebral amyloid angiopathy Aβ/Alzheimers disease Kidney AApoA1+AFib+ALys/Familial renal Skin Primary cutaneous ... Hereditary Cystatin C Amyloid Angiopathy Wikipedia External links [ edit ] Classification D ICD - 10 : E85.4+ I68.0* OMIM : ...
cerebral amyloid angiopathy + CHITOTRIOSIDASE DEFICIENCY Chromate Resistance Combined Congenital Deficiency of Intrinsic Factor ... familial hypocalciuric hypercalcemia + Familial Hypokalemia + FUCOSYLTRANSFERASE 6 DEFICIENCY Glucocorticoid Receptor ...
... and cerebral amyloid angiopathy. As such, the biological functions of APP and its processing products have been the subject of ... both point mutations and duplications of wild-type APP are linked to a subset of early onset of familial AD (FAD) ... while objective proof of renal amyloid regression either by serum amyloid P scintigraphy or biopsy is limited. We herein report ... Biochemically, deposition of the beta-amyloid (A beta) peptides p. Posted on April 26, 2021. by micr4174 ...
APP locus duplication causes autosomal dominant early-onset AD with cerebral amyloid angiopathy. [35] APP may be active early ... early form of familial AD (the dup-APP). In this condition, the triplication present varies in size. Still, only one APP ... APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006 ... amyloid angiopathy, and deposits of amyloid-beta (Abeta) protein in senile plaques. [14, 169] ...
... sporadic cerebral amyloid angiopathy [CAA] and chronic kidney disease) and the genetic (e.g., familial CAA, cerebral autosomal ... and cerebral amyloid angiopathy (CAA). In clinical-pathologic studies that factored in comorbid diseases, B-ASC was ... Infarto Cerebral/genética , Infarto Cerebral/patologia , CADASIL/patologia , Encéfalo/patologia , Angiopatia Amiloide Cerebral/ ... are prominent in the pathogenesis of cerebral MVD, making cerebral angiomyopathy an appropriate term to describe the spectrum ...
E5.242.373 Cerebral Amyloid Angiopathy, Familial C10.228.140.300.275.311 C14.907.253.329.311 Cerebral Angiography E1.370. ... 376.560.180 E1.370.350.578.937.180 E1.370.376.537.750.180 E5.629.937.180 Cerebral Ventriculography E1.370.376.560.190 E1.370. ...
E5.242.373 Cerebral Amyloid Angiopathy, Familial C10.228.140.300.275.311 C14.907.253.329.311 Cerebral Angiography E1.370. ... 376.560.180 E1.370.350.578.937.180 E1.370.376.537.750.180 E5.629.937.180 Cerebral Ventriculography E1.370.376.560.190 E1.370. ...
E5.242.373 Cerebral Amyloid Angiopathy, Familial C10.228.140.300.275.311 C14.907.253.329.311 Cerebral Angiography E1.370. ... 376.560.180 E1.370.350.578.937.180 E1.370.376.537.750.180 E5.629.937.180 Cerebral Ventriculography E1.370.376.560.190 E1.370. ...
E5.242.373 Cerebral Amyloid Angiopathy, Familial C10.228.140.300.275.311 C14.907.253.329.311 Cerebral Angiography E1.370. ... 376.560.180 E1.370.350.578.937.180 E1.370.376.537.750.180 E5.629.937.180 Cerebral Ventriculography E1.370.376.560.190 E1.370. ...
E5.242.373 Cerebral Amyloid Angiopathy, Familial C10.228.140.300.275.311 C14.907.253.329.311 Cerebral Angiography E1.370. ... 376.560.180 E1.370.350.578.937.180 E1.370.376.537.750.180 E5.629.937.180 Cerebral Ventriculography E1.370.376.560.190 E1.370. ...
E5.242.373 Cerebral Amyloid Angiopathy, Familial C10.228.140.300.275.311 C14.907.253.329.311 Cerebral Angiography E1.370. ... 376.560.180 E1.370.350.578.937.180 E1.370.376.537.750.180 E5.629.937.180 Cerebral Ventriculography E1.370.376.560.190 E1.370. ...
E5.242.373 Cerebral Amyloid Angiopathy, Familial C10.228.140.300.275.311 C14.907.253.329.311 Cerebral Angiography E1.370. ... 376.560.180 E1.370.350.578.937.180 E1.370.376.537.750.180 E5.629.937.180 Cerebral Ventriculography E1.370.376.560.190 E1.370. ...

No FAQ available that match "cerebral amyloid angiopathy familial"

No images available that match "cerebral amyloid angiopathy familial"